Invited review The cytology of malignant mesothelioma
2000; Wiley; Volume: 11; Issue: 3 Linguagem: Inglês
10.1046/j.1365-2303.2000.00247.x
ISSN1365-2303
Autores Tópico(s)Occupational exposure and asthma
ResumoCytopathologyVolume 11, Issue 3 p. 139-151 Invited review The cytology of malignant mesothelioma D. Whitaker, D. Whitaker Cytology Unit and Division of Tissue Pathology, The Western Australian Institute for Pathology and Medical Research, Perth, Western Australia.Search for more papers by this author D. Whitaker, D. Whitaker Cytology Unit and Division of Tissue Pathology, The Western Australian Institute for Pathology and Medical Research, Perth, Western Australia.Search for more papers by this author First published: 24 December 2001 https://doi.org/10.1046/j.1365-2303.2000.00247.xCitations: 112 Dr Darrel Whitaker, Cytology Unit and Division of Tissue Pathology, The Western Australian Institute for Pathology and Medical Research, Locked bag 2009, NEDLANDS 6009, Western Australia. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Burdorf A, Swuste PHJJ, Looman CWN. Estimating the future developments in mesothelioma mortality due to historical asbestos use and its consequences for public health. In: Source Book on Asbestos Diseases, Peters and Peters eds. Charlottesville: Lexis Law Publishing 1986; 145 167. 2 Karjalainen A, Pukkala E, Mattson K, Tammilehto L, Vainio H. Trends in mesothelioma incidence and occupational mesotheliomas in Finland in 1960–95. Scand J Work Environ Health 1997; 23: 266 70. 3 Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiology 1997; 145: 211 8. 4 Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535 9. 5 Peto J. The mesothelioma epidemic. Cytopathology. 1998; 9 (Suppl. 1): 52. 6 De Klerk NH & Armstrong BK. The epidemiology of asbestos and mesothelioma. In: Henderson DW, Shilkin KB, Langlois S, Le P, Whitaker D eds. Malignant Mesothelioma New York: Hemisphere, 1992; 223 50. 7 Butler EB & Berry AV. Diffuse mesotheliomas. Diagnostic criteria using exfoliative cytology. In: Bogovski P, Gilson JC, Timbrell V, Wagner JC eds. Biological Effects of Asbestos Lyon: International Agency for Research on Cancer 1973; 68 73. 8 Klempman S. The exfoliative cytology of diffuse pleural mesothelioma. Cancer 1962; 15: 691 704. 9 Roberts GH & Campbell GM. Exfoliative cytology of diffuse mesothelioma. J Clin Pathol 1972; 25: 577 82. 10 Whitaker D & Shilkin KB. Diagnosis of pleural malignant mesothelioma in life – a practical approach. J Pathol 1984; 143: 147 75. 11 Edge JR & Choudhury SL. Malignant mesothelioma of the pleura in Barrow-in-Furness. Thorax 1978; 33: 26 30. 12 Antman KH. Malignant mesothelioma. N Engl J Med 1980; 303: 200 2. 13 Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital. Acta Cytol 1984; 28: 37 45. 14 Ribak J, Lilis R, Suzuki Y, Penner L, Selikoff IJ. Malignant mesothelioma in a cohort of asbestos insulation workers: Clinical presentation, diagnosis, and causes of death. Br J Ind Med 1988; 45: 182 7. 15 Naylor B. The exfoliative cytology of diffuse malignant mesothelioma. J Pathol Bacteriol 1963; 86: 293 8. 16 Elmes PC & Simpson MJC. The clinical aspects of mesothelioma. Quart J Med 1976; 45: 427 9. 17 Sherman ME & Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic mesothelioma. Arch Pathol Lab Med 1990; 114: 845 51. 18 Stevens MW, Leong AS-Y, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma. A step-wide logistic regression analysis. Diagn Cytopathol 1992; 8: 333 41. 19 Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol 1986; 3: 196 203. 20 Whitaker D & Shilkin KB. The cytology of malignant mesothelioma in Western Australia. Acta Cytol 1978; 22: 67 70. 21 Kwee WS, Veldhuizen RW, Alons CL, Morawetz F, Boon ME. Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid. Acta Cytol 1982; 26: 401 6. 22 Tao LC. The cytopathology of mesothelioma. Acta Cytol 1979; 23: 209 13. 23 Whitaker D, Sterrett G, Shilkin K. Early diagnosis of malignant mesothelioma: the contribution of effusion and fine needle aspiration cytology and ancillary techniques. In: Peters GA, Peters BJ. eds. Sourcebook on Asbestos Diseases: Medical, Legal and Engineering Aspects, Vol 4 New York: Garland Law Publishing, 1989; 71 115. 24 Whitaker D, Sterrett G, Shilkin KB. Mesotheliomas. In: Gray W eds. Diagnostic Cytopathology New York: Churchill Livingstone, 1995; 195 224. 25 DiBonito L, Falconieri G, Colautti I, Gori DB, Dudine S, Giarelli L. Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diagn Cytopathol 1993; 9: 25 31. 26 Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997; 111: 106 9. 27 Teirstein AS. Diagnosing malignant pleural mesothelioma. Chest 1998; 114: 666 7. 28 Nguyen G-K, Akin M-R, Villanueva RR, Slatnik J. Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy. Diagn Cytopathol 1999; 21: 253 9. 29 Yu GH, Sack MJ, Baloch ZW, DeFrias DVS, Gupta PK. Occurrence of intercellular spaces (windows) in metastatic adenocarcinoma in serous fluids: a cytomorphologic, histochemical, and ultrastructural study. Diagn Cytopathol 1999; 20: 115 9. 30 Kho-Duffin J, Tao L-C, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol 1999; 20: 57 62. 31 Michael CW, King JAC, Hester RB. Con- focal laser scanning microscopy and three-dimensional reconstruction of cell clusters in serous fluids. Diagn Cytopathol 1997; 17: 272 9. 32 Takagi F. Studies on tumor cells in serous effusion. Am J Clin Pathol 1954; 24: 663 75. 33 Whitaker D. Cell aggregates in malignant mesothelioma. Acta Cytol 1977; 21: 236 9. 34 Triol JH, Conston AS, Chandler SVD. Distinguishing adenocarcinoma from mesothelioma in effusions (letter). Hum Pathol 1987; 18: 969. 35 Delahaye M, de Jong AA, Versnel MA, Hoogsteden HC, Teeling P, van der Kwast TH. Cytopathology of malignant mesothelioma. Reappraisal of the diagnostic value of collagen cores. Cytopathology 1990; 1: 137 45. 36 Becker SN, Pepin DW, Rosenthal DL. Mesothelial papilloma: a case of mistaken identity in a pericardial effusion. Acta Cytol 1976; 20: 266 8. 37 Spriggs AI & Jerrome DW. Benign mesothelial proliferation with collagen formation in pericardial fluid. Acta Cytol 1979; 23: 428 30. 38 Wojcik EM & Naylor B. 'Collagen Balls' in peritoneal washings. Prevalence, Morphology, Origin Significance. Acta Cytol 1992; 36: 466 70. 39 Whitaker D, Sterrett GF, Shilkin KB. Cytological appearances of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois S, LeP, Whitaker D eds. Malignant Mesothelioma New York: Hemisphere, 1992. 40 Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997; 17: 115 20. 41 Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994; 11: 237 45. 42 Illingworth AL, Young JA, Johnson GD. Immunofluorescent staining of metastatic carcinoma cells in serous fluid with carcinoembryonic antibody, epithelial membrane antibody, AUA-1 and Ber-EP4. Cytopathology 1994; 5: 270 81. 43 Tickman RJ, Cohen C, Varma VA, Fekete PS, DeRose PB. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness Immunohistochem Acta Cytol 1990; 34: 491 6. 44 Lee JS, Nam JH, Lee MC, Park CS, Juhng SW. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serous effusions. Acta Cytol 1996; 40: 631 6. 45 Nance KV & Silverman JF. Immunocytochemical panel for the identification of malignant cells in serous effusions. Am J Clin Pathol 1991; 95: 867 74. 46 Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito Jd Jr, O'leary TJ. Immunocytochemisry in the differential diagnosis of effusions: Use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993; 6: 179 84. 47 De Angelis M, Buley ID, Heryet A, Gray W. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathol 1992; 3: 111 7. 48 Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994; 10: 130 4. 49 Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993; 24: 347 54. 50 Dejmek A & Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994; 102: 255 64. 51 Dejmek A & Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression. Cytopathology 2000; 11: 8 17. 52 Singh G, Whiteside TL, Dekker A. Immunodiagnosis of mesothelioma. Use of antimesothelial cell serum in an indirect immunofluorescence assay. Cancer 1979; 43: 2288 96. 53 Donna A, Betta PG, Bellinger D, Marchisini A. New marker for mesothelioma: an immunoperoxidase study. J Clin Pathol 1986; 39: 961 8. 54 O'hara CJ, Corson JM, Pinkus GS et al ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 1990; 136: 421 8. 55 Abati A. OV632 as a possible marker for malignant mesothelioma: High expectations, low specificity. Diagn Cytopathol 1995; 12: 81 2. 56 Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology 1997; 8: 328 35. 57 Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31: 140 3. 58 Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037 46. 59 Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996; 192: 137 47. 60 Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998; 22: 1215 21. 61 Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998; 11: 929 33. 62 Mullick SS, Green LK, Ramzy I, Brown RW, Smith D, Gondon MM, Cagle PT. p53 Gene product in pleural effusions – practical use in distinguishing benign from malignant cells. Acta Cytol 1996; 40: 855 60. 63 Saleh HA, Bober P, Tabaczka P. Improved detection of adenocarcinoma of serous fluids with p53 immunocytochemistry. Acta Cytol 1998; 43: 1330 5. 64 Saleh H, Bober P, Tabaczka P. Value of Ki67 immunostain in identification of malignancy in serous effusions. Diag Cytopathol 1999; 20: 24 8. 65 Walts AE, Said JW, Shintaku IP. Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: immunocytochemical and ultrastructural localization in benign and malignant cells. Diagn Cytopathol 1987; 3: 41 9. 66 Singh HK, Silverman JF, Berns L, Haddad MG, Park HK. Significance of epithelial membrane antigen in the work-up of problematic serous effusions. Diagn Cytopathol 1995; 13: 3 7. 67 Lee JS, Nam JH, Lee MC, Park CS, Juhng SW. Immunohistochemcal panel for distinguishing between carcinoma and reactive mesothelial cells in serous effusions. Acta Cytol 1996; 40: 631 6. 68 Jensen ML & Johansen P. Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: a follow-up and comparative investigation. Diagn Cytopathol 1996; 15: 33 6. 69 Kortsik CS, Werner P, Freudenberg N, Virchow Jc Jr, Kroegel C, Pott M, Matthys H. Immunotycochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3-a new tumor marker. Lung 1995; 173: 79 87. 70 van der Kwast TH, Versnel MA, Delahaye M, de Jong A, Zondervan PE, Hoogsteden H. Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study. Acta Cytol 1988; 32: 169 74. 71 Leong AS-Y, Parkinson R, Milios J. 'Thick' cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma. Diagn Cytopathol 1990; 6: 9 13. 72 Leong ASY, Stevens MW, Mukherjee TM. Malignant mesothelioma: Cytologic diagnosis with histologic, immunohistochemical and ultrastructural correlation. Semin Diag Pathol 1992; 9: 141 50. 73 King JA & Tucker JA. Evaluation of membranous staining of mesothelioma. Cell Vis 1998; 5: 24 7. 74 Sterrett GF, Whitaker D, Shilkin KB, Walters MN-I. Fine needle aspiration cytology of malignant mesothelioma. Acta Cytol 1987; 31: 185 93. 75 Tao LC. Aspiration biopsy cytology of mesothelioma. Diagn Cytopathol 1989; 5: 14 21. Citing Literature Volume11, Issue3June 2000Pages 139-151 ReferencesRelatedInformation
Referência(s)